Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs

• Published in: Redox biology Vol. 67; p. 102900
• Main Authors: Li, Hongjiao, Wang, Yi, Yang, Fenfang, Feng, Shuang, Chang, Kaijing, Yu, Xinwen, Guan, Feng, Li, Xiang
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01-11-2023; Elsevier
• Subjects: BMMSCs; MDS/AML; Osteogenic/adipogenic differentiation; Research Paper; ROS; TWIST1; BMMSCs; TWIST1; MDS/AML; Osteogenic/adipogenic differentiation; ROS
• ISSN: 2213-2317; 2213-2317
• DOI: 10.1016/j.redox.2023.102900

Bone marrow-derived mesenchymal stem cells (BMMSCs) derived from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients often show a shift in the balance between osteoblastogenesis and adipogenesis. It was suggested that BMMSCs can potentially undergo reprogramming or educational processes. However, the results of reprogrammed differentiation have been inconclusive. In this study, clinical samples, co-culture models and mouse models were employed to explore the association of MDS/AML clonal cells and BMMSCs differentiation. We found that clonal MDS/AML cells promoted adipogenic differentiation and inhibited osteogenic differentiation of BMMSCs, which in turn promoted MDS expansion. Mass spectrometry and cytokine array were used to identify the molecules to drive the BMMSCs differentiation in MDS/AML. Mechanistically, highly expressed transcription factor TWIST1 in clonal MDS/AML cells induces MDS/AML cells to secrete more IFN-γ, which can induce oxidative stress through STAT1-dependent manner, ultimately causing enhanced adipogenic differentiation and inhibited osteogenic differentiation in BMMSCs. Overall, our findings suggest that targeting the driving oncogenes in malignant clonal cells, such as TWIST1, may offer new therapeutic strategies by remodeling the surrounding bone marrow microenvironment in the treatment of MDS/AML and other hematopoietic malignancies.